Within the biotech market,
Henry Schein Inc. (HSIC) has seen significant activity recently, reflected in fluctuating stock movements and stakeholders' positions. Their performance post-last earnings report indicated an impressive 6.4% rise. Stifel Financial Corp amplified its position by procuring 13,180 shares, similarly, Fmr LLC amplified their stake by buying 237,888 shares.
Mizuho began coverage with a neutral recommendation. HSIC plans to acquire
Acentus, a homecare medical products supplier, which led to a boost in their stock. Activist Ananym offered suggestions aimed at improving business profits and performance. Edgestream Partners L.P. and Centiva Capital LP reduced their positions by selling shares. Other investors seem to perceive HSIC as a long-term value stock despite their earnings being considered soft. Ananym Capital has been pushing for changes in HSIC. Despite economic and cyber challenges, HSIC beat earnings estimates in Q3 and expanded their medical supply segment with a $35 million Acentus acquisition. Nevertheless, HSIC's financial results for Q3 failed to meet expectations and the ongoing cyberattack impact forced them to cut their annual profit forecast. Moreover, despite challenging market conditions, HSIC's dental business continues to expand, carving a path towards recovery.
Henry Schein HSIC News Analytics from Thu, 04 Apr 2024 07:00:00 GMT to Sat, 07 Dec 2024 11:02:30 GMT -
Rating 7
- Innovation -2
- Information 8
- Rumor -5
